伏尼凝血素α(Vonicog Alfa (Baxalta)) - 药物靶点：vWF_在研适应症：冯·维勒布兰德病，血管性血友病3型，出血_专利_临床

概要

基本信息

药物类型

重组凝血因子

别名

Recombinant von Willebrand factor、rVWF、VEYVONDI

+ [19]

靶点

vWF

作用机制

vWF刺激剂(血管性血友病因子刺激剂)

治疗领域

遗传病与畸形血液及淋巴系统疾病其他疾病

在研适应症

冯·维勒布兰德病血管性血友病3型出血

非在研适应症-

原研机构

Baxalta, Inc.

在研机构

Baxalta, Inc.Takeda Development Center Americas, Inc.Baxalta Canada Corp.

+ [4]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2015-12-08),

血管性血友病3型

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

序列信息

Sequence Code 1166779

来源: *****

关联

14

项与伏尼凝血素α 相关的临床试验

NCT05582993 / Recruiting临床3期

A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis With rVWF in Children Diagnosed With Severe Von Willebrand Disease

The main aim of the study is to evaluate the effectiveness of prophylaxis with recombinant von Willebrand factor (rVWF) in children. This study will enroll those participants who have been previously treated with VWF product or with a plasma-derived VWF (pdVWF) product. In this study, participants will be treated with rVWF for 12 months.
During the study, participants will visit the study clinic 6 times after treatment initiation.

开始日期2024-11-06

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

NCT06118372 / Recruiting临床1期IIT

Safety and Tolerability of Recombinant Von Willebrand Factor Concentrate in Adult ECMO Patients with Major Bleeding: a Phase I Study

Adult patients on extracoporeal membrane oxygenation (ECMO) frequently experience bleeding, which is in part caused by acquired von Willebrand syndrome (vWS). Prior in vitro studies have shown that the addition of recombinant von Willebrand Factor (vWF) to ECMO patient blood samples, normalizes platelet adhesion and thrombus formation. This study is a phase I study, where adult ECMO patients with refractory bleeding will be treated with recombinant vWF a single time. The primary objectives are to evaluate the safety, tolerability, and pharmacokinetics of recombinant vWF in adult ECMO patients.

开始日期2024-10-03

申办/合作机构

University of Virginia

NCT03879135 / Active, not recruiting临床3期

A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)

The main aim of the study is to check effectiveness of rVWF (vonicog alfa) prophylaxis based on the annualized bleeding rate (ABR) of spontaneous (not related to trauma) bleeding episodes in pediatric and adult participants during the first 12 months on study treatment.
The participants will be treated with rVWF for a maximum of 3 years. Their von Willebrand Disease will be treated according to Investigational product (IP) dosing directions.

开始日期2019-04-01

申办/合作机构

Baxalta, Inc.

[+1]

100 项与伏尼凝血素α 相关的临床结果

登录后查看更多信息

100 项与伏尼凝血素α 相关的转化医学

登录后查看更多信息

100 项与伏尼凝血素α 相关的专利（医药）

登录后查看更多信息

381

项与伏尼凝血素α 相关的文献（医药）

2024-12-01·Blood Research

Real-world insights into the management of hemophilia A in Italy: treatment patterns and healthcare resource utilization

Article

作者: Cappuccilli, Maria ; Leogrande, Melania ; Perrone, Valentina ; Esposti, Luca Degli

Abstract:

Purpose:

This real-world analysis described the Hemophilia A (HA) population in Italy, evaluating drug utilization and consumption of factor VIII (FVIII) products of patients under prophylaxis and on-demand therapy.

Methods:

From Jan-2017 to Jun-2022, male patients with HA were identified through prescriptions of FVIII products [extended half-life FVIII, standard half-life recombinant FVIII, and plasma-derived FVIII (EHL FVIII, SHL rFVIII, and pdFVIII, respectively)], or emicizumab or FVIII plus von Willebrand factor or HA-related hospitalization using administrative flows of Italian healthcare entities. Patients on treatment with FVIII products during 2021–2022 were stratified by treatment regimen (prophylaxis/on-demand). The mean annual consumption expressed in International Units (IU) of EHL FVIII and SHL FVIII in patients treated during 2021–2022 having at least 12-month follow-up were assessed.

Results:

Among included HA patients, 145 (39.5%) received EHL FVIII and 222 (60.5%) SHL FVIII. Of 165 patients on prophylaxis, 105 (64%) received an EHL FVIII and 60 (36%) an SHL FVIII. The mean annual consumption of FVIII was 336,700 IU (median 319,000 IU) for EHL FVIII and 440,267 IU (median 360,500 IU) for SHL FVIII. Specifically, for patients on EHL FVIII, the most common drugs were efmoroctocog alfa (N = 51) and damoctocog alfa pegol (N = 50), followed by turoctocog alfa pegol (N = 25) and rurioctocog alfa pegol (N = 19). Of 702 HA patients initially treated with FVIII products, 74 (10.5%) switched to emicizumab during follow-up.

Conclusion:

These findings revealed an extensive use of EHL FVIII products, suggesting growing efforts from clinicians to optimize prophylactic strategies and achieve better bleeding protection.

2024-11-01·HAEMOPHILIA

Efficacy and safety of a recombinant von Willebrand factor treatment in acquired von Willebrand syndrome in case of bleeding and surgical procedures

Article

作者: Hittinger, Xavier ; Fouassier, Marc ; Babuty, Antoine ; Sattler, Laurent ; Drillaud, Nicolas ; Pierre, Léa ; Desprez, Dominique ; Trossaërt, Marc ; Wimmer, Jordan ; Herb, Agathe ; Feugeas, Olivier ; Ternisien, Catherine ; Gérout, Anne‐Cécile

Abstract:

Introduction:

Acquired von Willebrand syndrome (AVWS) is a rare haemorrhagic disorder. The prophylaxis and treatment of bleeding before surgery are complex. Since 2018, a new recombinant VWF (rVWF) concentrate that contains no factor VIII (FVIII) but a high amount of high molecular weight VWF multimers has been available in France.

Aim:

To describe the real‐world experience of using rVWF in non‐surgical bleeding and surgical procedures in patients with AVWS.

Methods:

Fifteen bleeding episodes in seven patients and 16 surgeries in 10 patients were retrospectively analysed in t French haemostasis centres.

Results:

During bleeding, the median number of infusions was only 1 (range 1–27) with a median loading dose of 58 IU/kg (range 17–116) rVWF and a total median dose of 65 IU/kg (range 35–1488) rVWF. Bleeding control was rated markedly effective in 73% (11/15) of the cases and ineffective in 27% (4/15).During surgeries, the median number of infusions was 3 (range 1–8) with a preoperative loading dose of 60 IU/kg (range 23–118) rVWF and a total median dose of 123 IU/kg (range 31–542). The overall clinical efficacy was qualified as excellent, good and poor (ISTH criteria) in respectively 7 (43%), 6 (38%) and 3 (19%) procedures.There was no accumulation of VWF or FVIII during postoperative monitoring. No thromboembolic events nor adverse events were reported.

Conclusion:

This French ‘real‐world’ experience shows that rVWF could be of interest in the treatment and prophylaxis of bleeding in patients with AVWS, with no clinically significant safety concern.

2024-11-01·Research and Practice in Thrombosis and Haemostasis

Prophylaxis in von Willebrand disease with von Willebrand factor concentrate and nonfactor therapies

Article

作者: van Kwawegen, Calvin B ; Leebeek, Frank W G

This manuscript summarizes the current status of prophylaxis and novel potential therapies to prevent bleeding in patients with von Willebrand disease (VWD). VWD is the most common inherited bleeding disorder, which is associated mainly with mucocutaneous bleeding and bleeding during surgical and dental interventions. More severely affected VWD patients, mostly those with type 2 and type 3, can also suffer from joint, muscle, and gastrointestinal bleeds. Most patients with mild and moderate VWD are treated with desmopressin. The majority of patients with type 2 and 3 are treated with von Willebrand factor concentrates, with or without factor VIII. These patients suffer from severe and frequent bleeds and may require regular infusions of von Willebrand factor concentrate to prevent bleeding, so-called prophylaxis, 1 to 3 times per week. In this article, we review the current status of prophylaxis in VWD. We will also discuss emerging treatments that may be used as long-term prophylaxis in patients with severe VWD. We include relevant new data on this topic that were presented during the 2024 International Society on Thrombosis and Haemostasis (ISTH) Congress.

24

项与伏尼凝血素α 相关的新闻（医药）

2024-12-14

·思齐俱乐部

全球最贵药上新：基因疗法的奇迹与天价之痛

全球最昂贵药物top 10，有5个是基因疗法药物。辉瑞今年获批的中重度B型血友病疗法Beqvez定价350万美元，一定价就坐上“最贵药物”的交椅。基因治疗，唯一可能治愈的方法血友病是一种由于X染色体上凝血因子基因突变所致的遗传性出血性疾病。血友病主要包括血友病A（hemophilia A，HA）和血友病B（hemophilia B，HB），它们分别是凝血因子Ⅷ（FⅧ）和IX（FⅨ）基因缺乏导致的罕见遗传性出血性疾病。患者常伴有终身凝血功能障碍，导致关节出血和其他严重并发症。目前主要的治疗方法是凝血因子替代疗法。但长期频繁的注射用药往往导致患者依从性差，容易产生抑制性抗体，从而影响治疗效果。虽然现在延长半衰期的新型凝血因子药物、人源化双特异性抗体以及抗组织因子途径抑制剂单克隆抗体等用于疾病治疗，在给药方式和作用持续时间上已有很大进步，但它们仍无法治愈血友病。对于血友病患者来说，基因治疗几乎是唯一可能治愈的方法。通过基因治疗将凝血因子安全递送到患者细胞中，让其长期稳定表达，并使用尽可能低的载体剂量，来改善患者的出血情况和凝血功能，是治疗疾病的最终目标。已获批药物，针针天价目前已经获批的血友病基因疗法中，以下几款比较具有代表性。 HYMPAVZI™（马塔西单抗）药物类型：抑制物抗体（抗TFPI）适应症：血友病A或血友病B 价格：未公布 2024年11月，辉瑞血友病新型疗法HYMPAVZI™（马塔西单抗）获欧盟委员会（EC）批准，用于规律性治疗患有不伴凝血因子抑制物的重型血友病A（先天性凝血VIII因子缺乏症，FVIII<1%）或者重型血友病B（先天性凝血IX因子缺乏症，FIX<1%）的12岁及以上且体重不低于35公斤的患者，以减少出血的发作。马塔西单抗是欧盟（EU）首个且唯一获批用于治疗血友病A或血友病B的抗组织因子途径抑制物抗体（抗TFPI），也是欧盟首个通过预充式自动注射笔给药的血友病创新疗法，只需每周一次、皮下注射、给药便捷。伏尼凝血素α（维因止®）药物类型：重组血管性血友病因子（rVWF）适应症：血管性血友病（VWD）价格：未公布 2024年8月，武田旗下创新药物重组血管性血友病因子（rVWF）注射用伏尼凝血素α（商品名：维因止®）正式获得国家药品监督管理局（NMPA）批准上市，用于血管性血友病（VWD）成人患者（年龄为18岁及以上）的按需治疗和出血事件控制，以及围手术期出血管理。注射用伏尼凝血素α是全球首个且目前唯一一个重组血管性血友病因子产品[1]，其获批填补了中国血管性血友病领域的临床治疗空白，有望为患者带来精准治疗的创新选择。 Beqvez 药物类型：中和抗体适应症：中重度B型血友病成人患者价格：350万美元 4月26日，辉瑞宣布美国FDA已批准其BEQVEZ（fidanacogene elaparvovec-dzkt）用于治疗目前使用因子IX（FIX）预防治疗、当前或既往有危及生命的出血、或反复发生严重自发性出血的血友病B成人患者。且患者体内没有针对腺相关病毒血清型Rh74var（AAVRh74var）衣壳的中和抗体。BEQVEZ是一种一次性治疗，旨在使血友病B患者能够自行产生FIX，而非像目前的标准治疗那样需要定期静脉输注FIX。 Hemgenix（AMT060）药物类型：AAV5 价格：350万美元由UniQure 公司开发Hemgenix（AMT060）是一款基于腺相关病毒5（adeno-associated virus 5，AAV5）载体的基因疗法，该药物搭载有FⅨ基因变体（FⅨ-Padua），通过静脉给药后，该基因可在肝脏中表达FⅨ分泌入血液发挥凝血功能。该AAV基因疗法在2022年11月获美国食品与药品管理局（Food and Drug Administration，FDA）批准上市，这也是全球首款获批上市用于治疗HB的基因疗法，因为良好的疗效和安全性数据，Hemgenix于次年2月在欧盟委员会获批有条件营销授权上市。 Roctavian 药物类型：AAV5 适应症：甲型血友病（HA）价格：290万美元/疗程 Roctavian是另一款以AAV5为载体的基因治疗药物，通过静脉给药的形式，递送外源性B结构域删除（B domain deleted，BDD）的FⅧ变异体基因肝细胞定向整合和高效表达，达到治疗HA的目的。该药通过静脉单次给药，使患者具有自身表达凝血Ⅷ因子的能力，无需继续进行预防性治疗，极大地减轻HA患者的治疗负担，2022年8月欧盟委员会正式授予Roctavian用于治疗重型HA的有条件营销授权许可。血友病市场规模正在增长，预计到2028年将达到数十亿元的市场规模。据不完全统计，目前基因治疗血友病在研药物约40余种。照片来源：新浪医药辉瑞、赛诺菲、拜耳、武田等跨国企业均有相关药物进入临床；国内公司中国生物、国药集团、华兰生物新等也在进行各个阶段的临床研究。基因疗法效果虽好，但价格依然是逃不开的话题。业内多看好基因疗法治疗血友病的前景，但短期内很难做到广泛适用。来源：新浪医药作者：张杰商务合作 130 6172 3098 zakk.cui@siqibest.com 点击阅读原文了解更多

基因疗法上市批准临床结果

2024-12-13

·echemi

Gene Therapy: 5 Drugs in the Top Ten, Most Expensive at $3.5 Million

In the current global pharmaceutical market, gene therapy drugs occupy a significant portion of the most expensive drug rankings, with five listed in the top ten. Pfizer's recently approved treatment for moderate to severe Hemophilia B, Beqvez, is priced at a staggering $3.5 million, making it one of the highest-priced drugs in history. Hemophilia is a hereditary bleeding disorder primarily divided into Hemophilia A and B, caused by mutations in the genes for clotting factors VIII and IX, respectively. Patients typically suffer from lifelong coagulation dysfunction, leading to joint bleeding and other severe complications. Currently, replacement therapies with clotting factors are the main treatment method, but frequent long-term injections can lead to poor patient compliance and may produce inhibitory antibodies, affecting treatment efficacy. Although new clotting factor drugs, humanized bispecific antibodies, and monoclonal antibodies that inhibit the tissue factor pathway have made advancements in administration methods and duration of action, these methods still cannot cure hemophilia. For hemophilia patients, gene therapy offers a glimmer of hope for a cure. Through gene therapy, clotting factors can be safely delivered into the patient's cells for long-term stable expression, thereby improving bleeding conditions and coagulation function, which is the ultimate goal of hemophilia treatment. Currently, several gene therapy drugs for hemophilia have been approved, including: HYMPAVZI™ (Matizumab): An anti-TFPI antibody suitable for patients with Hemophilia A or B, developed by Pfizer, approved by the European Commission in November 2024. Vonvendi (Veyinzh®): A recombinant von Willebrand factor (rVWF) for adult patients with von Willebrand disease (VWD), developed by Takeda, approved by China's National Medical Products Administration in August 2024. Beqvez: A neutralizing antibody for adult patients with moderate to severe Hemophilia B, developed by Pfizer, priced at $3.5 million. Hemgenix (AMT060): A gene therapy based on adeno-associated virus 5 (AAV5) for patients with Hemophilia B, developed by UniQure, approved by the U.S. FDA in November 2022. Roctavian: Also based on the AAV5 vector, this gene therapy is for patients with Hemophilia A (HA), priced at $2.9 million per treatment, developed by BioMarin, and received conditional marketing authorization from the European Commission in August 2022. As the hemophilia market continues to grow, it’s expected to reach a scale of billions by 2028. Currently, over 40 gene therapies for hemophilia are in research, with multinational companies like Pfizer, Sanofi, Bayer, and Takeda, as well as domestic firms like China National Pharmaceutical Group and Hualan Biologicals, actively conducting clinical studies. Despite the enormous potential of gene therapy in treating hemophilia, the high costs remain a significant barrier to its widespread adoption.

基因疗法上市批准

2024-10-29

·上海医药

上海医药2024年三季报：深化生态圈建设，加速高质量发展

上海医药集团股份有限公司（601607.SH；02607.HK）发布2024年三季报。报告期内，公司实现营业收入2,096.29亿元，同比增长6.14%，其中医药工业实现销售收入182.84亿元；医药商业实现销售收入1,913.45亿元，同比增长8.28%。报告期内，公司实现归母净利润40.54亿元，同比增长6.78%。其中：工业业务贡献利润18.64亿元，同比增长3.58%；商业业务贡献利润26.52亿元，同比增长0.26%；扣非归母净利润36.86亿元，同比增长11.56%。前三季度，公司实现经营性现金流净流入27.83亿元，同比增长20.87%。创新为驱动，构建生态圈上海医药深入贯彻落实上海市委市政府加快发展生物医药先导产业的部署要求，积极融入全市发展大局，聚焦主责主业，奋力打造世界一流企业。公司以创新为核，稳步推进新药管线进程，截至报告期末，处于临床申请获得受理及进入后续临床研究阶段的新药管线共有60项，其中创新药46项（含美国临床II期3项）。 9月10日，上海生物医药前沿产业创新中心（上海前沿）正式开业运营，深度融合“产学研医资”资源，聚集创新要素，加快构建开源创新生态圈，肩负起“链主”企业的责任与担当。截至公告日，上海前沿已吸引了众多高质量合作伙伴入驻。8月，上海前沿与赛多利斯集团签订战略合作协议，聚焦生物医药创新孵化与转化。9月，上海康健生细胞技术有限公司正式揭牌，上海医药与上海交通大学医学院附属瑞金医院、上海交通大学医学院附属上海儿童医学中心、中国干细胞集团有限公司正式签署四方战略合作协议，携手共拓细胞治疗战略性新赛道；拜耳Co.Lab入驻上海前沿，双方将深化产业生态合作；第二十三届浦江学科交叉论坛在上海前沿成功举办，上海医药与上海市生物医药技术研究院签署协议，加强产研联动，促进创新链、人才链、产业链衔接，加快创新药物研发转化。10月，上海医药与拜耳健康消费品签署战略合作协议，拜耳健康消费品中国创新合作中心落户上海前沿，预计投资约2,000万欧元。深耕大品种，扬中药美名上海医药拥有8家主要直管中药企业和9个中药核心品牌，凭借自身中药资源禀赋，紧抓中药行业发展机遇，持续推进大品种和大品牌战略。报告期内，公司中药六大品种“养心氏片”、“瘀血痹胶囊”、“冠心宁片”、“八宝丹”、“胃复春”、“银杏酮酯”的二次开发稳步进行，循证医学研究持续推进，病例入组数进一步增加，中药板块业务保持良好发展态势。商业重质效，赋能全链条在医药流通领域，公司积极探索新商业模式，深耕创新业务领域，打造创新药全生命周期健康服务模式，为高质量发展蓄势赋能。2024年前三季度，公司成功引入进口总代品种13个；药品CSO合约推广业务实现销售收入约61亿元，同比增幅达176.3%；非药业务也实现良好增长，器械大健康业务销售约326亿元，同比增长11.9%。益药·药房致力于打造全国最大一体化运营的药房网络，成为创新药全国首单落地的首选。2024年10月，上海医药全资子公司上药控股与武田中国在上药云健康益药·药房综合旗舰店就武田在中国上市的创新药“助因止”、“维因止”（重组血管性血友病因子注射用伏尼凝血素α）举行交流会暨新品签约仪式，赋能新药上市，惠及更多患者。凭借卓越的企业实力，上海医药在2024《财富》世界500强榜单中排名跃升至第411位，蝉联“全球制药企业50强”位列第42位，同时位列“2024上海企业100强”第13位及“上海制造业100强”第3位，持续保持领先地位。作为医药行业的领军企业，上海医药坚持以创新为驱动，坚定走高科技高质量发展之路，以全球视野整合资源，积极开拓新业务，发挥“链主”作用，加速培育生物医药产业新质生产力，致力于为推动中国生物医药产业发展作出更大贡献，为股东和投资者创造更大价值。

财报

100 项与伏尼凝血素α 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08681	伏尼凝血素α	B02BD10	DB12872

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
冯·维勒布兰德病	欧盟	Baxalta Innovations GmbH	2018-08-31
冯·维勒布兰德病	冰岛	Baxalta Innovations GmbH	2018-08-31
冯·维勒布兰德病	列支敦士登	Baxalta Innovations GmbH	2018-08-31
冯·维勒布兰德病	挪威	Baxalta Innovations GmbH	2018-08-31
血管性血友病3型	美国	Takeda Pharmaceuticals U.S.A., Inc.	2015-12-08

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
出血	临床3期	美国	Baxalta, Inc.	2011-11-01
出血	临床3期	日本	Baxalta, Inc.	2011-11-01
出血	临床3期	澳大利亚	Baxalta, Inc.	2011-11-01
出血	临床3期	奥地利	Baxalta, Inc.	2011-11-01
出血	临床3期	比利时	Baxalta, Inc.	2011-11-01
出血	临床3期	保加利亚	Baxalta, Inc.	2011-11-01
出血	临床3期	加拿大	Baxalta, Inc.	2011-11-01
出血	临床3期	德国	Baxalta, Inc.	2011-11-01
出血	临床3期	印度	Baxalta, Inc.	2011-11-01
出血	临床3期	意大利	Baxalta, Inc.	2011-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASH2024	N/A	-	-	Continuous prophylaxis with recombinant VWF	壓網構窪選顧願鏇壓繭(襯醖獵夢網膚簾夢糧構) = One participant reported 9 adverse events (AEs); all AEs were resolved and determined to be unrelated to rVWF treatment 壓餘選鏇蓋遞蓋遞齋鹹 (選願醖鹽鬱憲積醖淵鏇 ) 更多	-	2024-12-08
ISTH2023	N/A	冯·维勒布兰德病	82	Recombinant von Willebrand factor (rVWF)	廠鏇願繭淵餘廠襯醖選(範醖糧鹹觸鬱積築壓醖) = 憲遞糧艱蓋壓鏇遞鹹築窪願願網製構獵構願繭 (願網願獵憲積蓋鑰鹹糧 )	-	2023-06-24
ISTH2022	N/A	2型血管性血友病	-	Recombinant VWF concentrate	鹹製醖醖積築餘襯觸顧(範範繭鹹艱遞積憲選鏇) = 網鹽範壓築構艱膚艱衊繭獵餘範構鹹壓餘積壓 (醖艱艱繭衊鏇醖鑰壓獵 ) 更多	-	2022-07-09
NCT02973087 (Pubmed \| Circulation \| Blood) 人工标引	临床3期	冯·维勒布兰德病	23	Recombinant von Willebrand factor (Prior On-Demand group)	膚餘壓壓築窪憲壓憲網(範廠簾夢簾製築製壓廠) = 淵願網繭簾衊衊顧積齋顧繭蓋選顧願製餘網鏇 (鏇夢壓衊壓顧醖簾齋選 )	积极	2022-04-19
				Recombinant von Willebrand factor (Switch group)	膚餘壓壓築窪憲壓憲網(範廠簾夢簾製築製壓廠) = 範願範築觸蓋構壓遞膚顧繭蓋選顧願製餘網鏇 (鏇夢壓衊壓顧醖簾齋選 )
NCT02973087 (CTgov)	临床3期	冯·维勒布兰德病	29	VWF concentrate+rVWF (Prior On-demand Participants)	構範願簾壓構醖願鹽獵(製簾範廠齋遞積積齋顧) = 憲壓願衊艱衊範鹽醖膚網鬱餘窪顧獵艱選網餘 (餘築憲顧構廠艱窪簾襯, 築夢夢範鏇願觸夢製鏇 ~ 憲選築鏇憲窪膚顧網鹹) 更多	-	2021-08-06
				VWF concentrate+rVWF (Switch Participants)	構範願簾壓構醖願鹽獵(製簾範廠齋遞積積齋顧) = 膚範衊膚淵網鬱繭餘鑰網鬱餘窪顧獵艱選網餘 (餘築憲顧構廠艱窪簾襯, 鹹鏇願膚壓顧獵餘廠窪 ~ 艱築鹽夢窪艱鑰艱鬱蓋) 更多
ISTH2021	N/A	乳腺癌 Von Willebrand Factor	-	Von Willebrand Factor	淵齋簾選遞積膚鏇鹹艱(鑰襯蓋網窪淵範觸衊襯) = 鬱淵鏇糧製膚鏇繭構鹹窪構範衊選蓋築鹹壓網 (築遞醖夢構願齋膚鬱願 )	-	2021-07-17
				Von Willebrand Factor	鹹願憲艱齋齋餘衊艱壓(網衊廠網衊築築廠艱餘) = 範壓願簾製餘網膚遞齋窪鏇願網簾積鹹廠積積 (築積衊廠獵襯積憲膚鏇 ) 更多
MO763 (ERA2021)	N/A	动静脉瘘 von Willebrand Factor (VWF)	-	Von Willebrand factor (Wild-type mice)	壓夢簾衊鏇淵廠鹽選齋(簾餘觸廠餘糧鏇鬱鏇襯) = 夢製餘繭鹽淵築淵膚淵衊膚鹽齋餘簾艱繭餘餘 (築範鏇鏇築淵糧鹽鬱夢 )	积极	2021-05-29
				Von Willebrand factor (VWF deficient mice)	餘憲壓淵遞艱築艱醖襯(繭願網構鏇選襯醖夢鬱) = 襯觸憲繭廠鏇簾廠簾醖窪築齋鏇網壓齋繭襯鑰 (遞鏇範襯鹽醖觸獵醖遞 ) 更多
ISC2021	N/A	脑卒中 Von Willebrand Factor (VWF)	-	Von Willebrand Factor (VWF) (ipsilateral LMCs)	簾範齋築範鬱膚遞襯構(遞衊襯積選鬱鬱淵鬱積) = 夢範廠鑰選蓋齋製鏇積鏇窪艱鏇構膚鹽築糧餘 (衊糧壓築廠膚膚廠壓壓 ) 更多	-	2021-03-01
				Von Willebrand Factor (VWF) (contralateral LMCs)	鏇鬱鏇糧糧繭獵餘遞願(壓選餘艱衊鏇繭積繭選) = 製獵範襯廠艱積範遞夢鹽選築選鹽觸範醖範蓋 (窪鑰衊憲糧鹽膚鬱願簾 )
ISTH2020	N/A	-	-	Recombinant multimeric von Willebrand factor	鬱築繭繭鏇選夢繭製夢(觸遞鏇壓淵鹽繭艱範製) = 夢鏇鬱艱構鹹壓築糧鏇齋窪襯範繭襯鬱製顧願 (醖鬱製積糧製夢鬱製範 )	-	2020-07-12
				Recombinant Factor VIII	鬱築繭繭鏇選夢繭製夢(觸遞鏇壓淵鹽繭艱範製) = 醖鏇願壓構遞願壓顧獵齋窪襯範繭襯鬱製顧願 (醖鬱製積糧製夢鬱製範 )
ISTH2020	N/A	CREST综合征	-	Recombinant von Willebrand Factor	醖醖繭壓範窪繭繭廠齋(衊鏇壓淵簾衊衊構鹹窪) = 淵餘襯鬱鹹醖艱艱艱製膚廠壓衊壓憲齋鹽築壓 (鬱壓鑰願餘鏇築膚鬱遞 )	-	2020-07-12